TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2018
At a glance
- Drugs Rucaparib (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms TRITON2
- Sponsors Clovis Oncology
- 31 Aug 2018 Biomarkers information updated
- 08 May 2018 According to a Clovis Oncology media release, data from this study will be presented at the European Society for Medical Oncology 2018.
- 26 Feb 2018 According to a Clovis Oncology media release, the company plans to present initial data from this ongoing study at a medical meeting in Fall 2018.